Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Recursion PharmaceuticalsRXRX -2.67%63 Debt-to-Equity is 0.07 as of Jun. 2026, which is 30% below its 10-year median of 0.10. GuruFocus rates RXRX with a GF Score™ of 63/100 and a GF Value™ of $3.02 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 956 Biotechnology companies, Recursion Pharmaceuticals ranks better than 65.27% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Recursion Pharmaceuticals's Debt-to-Equity or its related term are showing as below:
RXRX'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.13 Med: 0.1 Max: 0.17
Current: 0.07
During the past 7 years, the highest Debt-to-Equity Ratio of Recursion Pharmaceuticals was 0.17. The lowest was -0.13. And the median was 0.10.
RXRX's Debt-to-Equity is ranked better than 65.27% of 956
companies
in the Biotechnology industry
Industry Median: 0.16
vs RXRX: 0.07
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Recursion Pharmaceuticals Debt-to-Equity Related Terms
Recursion Pharmaceuticals Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RXRX vs INVA, TSHA, MLTX: Debt-to-Equity Comparison
For the Biotechnology subindustry, Recursion Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Recursion Pharmaceuticals Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Recursion Pharmaceuticals's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Recursion Pharmaceuticals's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Recursion Pharmaceuticals (RXRX) has a Debt-to-Equity of 0.07 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Recursion Pharmaceuticals and its competitors. This is 30% below median its historical median of 0.10. According to the industry distribution chart, Recursion Pharmaceuticals ranks #332 out of 956 companies in the Biotechnology industry, placing it in the top 34.7%.
Is Recursion Pharmaceuticals' Debt-to-Equity too high?
Recursion Pharmaceuticals' current Debt-to-Equity of 0.07 is 30% below median its 10-year median of 0.10. The Biotechnology industry median Debt-to-Equity is 0.16. Recursion Pharmaceuticals' value of 0.07 is 56.3% below this industry median. Based on the distribution chart, Recursion Pharmaceuticals ranks #332 out of 956 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Recursion Pharmaceuticals has a GF Score™ of 63/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Recursion Pharmaceuticals' Debt-to-Equity compare to INVA and TSHA?
According to the Biotechnology industry distribution chart, Recursion Pharmaceuticals ranks #332 out of 956 companies for Debt-to-Equity. This puts Recursion Pharmaceuticals in the upper half of its industry. The industry median Debt-to-Equity is 0.16. Recursion Pharmaceuticals' value of 0.07 is 56.3% below this benchmark. While the company's 10-year median is 0.10 vs. the industry median of 0.16, Recursion Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Recursion Pharmaceuticals's current Debt-to-Equity of 0.07 is 56.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Recursion Pharmaceuticals and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Recursion Pharmaceuticals's current Debt-to-Equity is 0.07, which is 30% below median its own 10-year median of 0.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recursion Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Recursion Pharmaceuticals (RXRX) is currently considered Modestly Overvalued. The stock's GF Value™ is $3.02, compared to a current price of $3.46 — trading 14.6% above its estimated fair value. The current Debt-to-Equity is 0.07, which is 30% below median its 10-year median of 0.10 and 56.3% below the Biotechnology industry median of 0.16. Recursion Pharmaceuticals' overall GF Score™ is 63/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Recursion Pharmaceuticals (RXRX), the current Debt-to-Equity is 0.07 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Recursion Pharmaceuticals (RXRX) Overvalued in 2026?
Based on GuruFocus' analysis, Recursion Pharmaceuticals stock appears to be overvalued.
The current stock price of $3.46 is trading 14.6% above its estimated GF Value™ of $3.02.
GuruFocus considers Recursion Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for RXRX:
Debt-to-Equity: 0.07 (30% below median its 10-year median of 0.10)
GF Value™: $3.02 vs. price of $3.46 (14.6% above fair value)
Industry Position: 56.3% below the Biotechnology median (#332 of 956)
No single metric tells the full story. See the RXRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
63GF Score
Get the complete analysis for RXRX
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RXRX has been successfully added to your 
